Quantinno Capital Management LP Acquires 17,648 Shares of Fresenius Medical Care AG (NYSE:FMS)

Quantinno Capital Management LP increased its holdings in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 16.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,726 shares of the company's stock after acquiring an additional 17,648 shares during the quarter. Quantinno Capital Management LP's holdings in Fresenius Medical Care were worth $2,892,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC lifted its position in shares of Fresenius Medical Care by 8.4% in the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after purchasing an additional 441 shares during the period. PNC Financial Services Group Inc. boosted its position in Fresenius Medical Care by 5.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,278 shares of the company's stock valued at $210,000 after acquiring an additional 442 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after acquiring an additional 806 shares during the period. DAVENPORT & Co LLC raised its position in shares of Fresenius Medical Care by 1.5% in the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock worth $1,316,000 after acquiring an additional 862 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Fresenius Medical Care by 16.6% in the 4th quarter. Signaturefd LLC now owns 7,393 shares of the company's stock valued at $167,000 after purchasing an additional 1,052 shares during the period. Institutional investors own 8.37% of the company's stock.

Fresenius Medical Care Stock Down 1.2%

Shares of NYSE FMS traded down $0.35 during trading on Friday, reaching $28.97. The company had a trading volume of 500,718 shares, compared to its average volume of 327,295. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a market cap of $17.00 billion, a PE ratio of 23.94, a P/E/G ratio of 0.76 and a beta of 0.85. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $30.46. The business's 50-day moving average is $25.53 and its 200 day moving average is $24.04.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The firm had revenue of $5.54 billion during the quarter, compared to analysts' expectations of $4.71 billion. As a group, equities analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be issued a dividend of $0.7871 per share. This represents a dividend yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. This is an increase from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's dividend payout ratio (DPR) is presently 49.11%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Morgan Stanley reaffirmed an "underweight" rating on shares of Fresenius Medical Care in a research note on Thursday, May 15th. Truist Financial increased their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday, May 12th. Finally, Wall Street Zen started coverage on shares of Fresenius Medical Care in a research report on Tuesday, May 20th. They set a "strong-buy" rating for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $27.80.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.